Structural Snapshots Illustrate the Catalytic Cycle of β-galactocerebrosidase, the Defective Enzyme in Krabbe Disease

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2013 Dec 4

PMID 24297913

Citations 22

Authors

Chris H Hill

Stephen C Graham

Randy J Read

Janet E Deane

Affiliations

Soon will be listed here.

Abstract

Glycosphingolipids are ubiquitous components of mammalian cell membranes, and defects in their catabolism by lysosomal enzymes cause a diverse array of diseases. Deficiencies in the enzyme β-galactocerebrosidase (GALC) cause Krabbe disease, a devastating genetic disorder characterized by widespread demyelination and rapid, fatal neurodegeneration. Here, we present a series of high-resolution crystal structures that illustrate key steps in the catalytic cycle of GALC. We have captured a snapshot of the short-lived enzyme-substrate complex illustrating how wild-type GALC binds a bona fide substrate. We have extensively characterized the enzyme kinetics of GALC with this substrate and shown that the enzyme is active in crystallo by determining the structure of the enzyme-product complex following extended soaking of the crystals with this same substrate. We have also determined the structure of a covalent intermediate that, together with the enzyme-substrate and enzyme-product complexes, reveals conformational changes accompanying the catalytic steps and provides key mechanistic insights, laying the foundation for future design of pharmacological chaperones.

Citing Articles

Structure and function of a β-1,2-galactosidase from Bacteroides xylanisolvens, an intestinal bacterium.

Nakazawa Y, Kageyama M, Matsuzawa T, Liang Z, Kobayashi K, Shimizu H Commun Biol. 2025; 8(1):66.

PMID: 39820076 PMC: 11739564. DOI: 10.1038/s42003-025-07494-1.

Late-onset Krabbe disease presenting as spastic paraplegia - implications of GCase and CTSB/D.

Machtel R, Dobert J, Hehr U, Weiss A, Kettwig M, Laugwitz L Ann Clin Transl Neurol. 2024; 11(7):1715-1731.

PMID: 38837642 PMC: 11251474. DOI: 10.1002/acn3.52078.

Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos.

Guerra J, Belleri M, Paiardi G, Tobia C, Capoferri D, Corli M Comput Struct Biotechnol J. 2024; 23:1397-1407.

PMID: 38596316 PMC: 11002810. DOI: 10.1016/j.csbj.2024.03.023.

Novel genetic variant associated with globoid cell leukodystrophy in a family of mixed breed dogs.

Hammack S, Hague D, Vieson M, Esdaile E, Hughes S, Bellone R J Vet Intern Med. 2023; 37(5):1710-1715.

PMID: 37593836 PMC: 10473001. DOI: 10.1111/jvim.16822.

Altered plasma membrane abundance of the sulfatide-binding protein NF155 links glycosphingolipid imbalances to demyelination.

McKie S, Nicholson A, Smith E, Fawke S, Caroe E, Williamson J Proc Natl Acad Sci U S A. 2023; 120(14):e2218823120.

PMID: 36996106 PMC: 10083573. DOI: 10.1073/pnas.2218823120.

References

Yuzwa S, Macauley M, Heinonen J, Shan X, Dennis R, He Y . A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol. 2008; 4(8):483-90. DOI: 10.1038/nchembio.96. View

Giri S, Khan M, Rattan R, Singh I, Singh A . Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death. J Lipid Res. 2006; 47(7):1478-92. DOI: 10.1194/jlr.M600084-JLR200. View

Guce A, Clark N, Salgado E, Ivanen D, Kulminskaya A, Brumer 3rd H . Catalytic mechanism of human alpha-galactosidase. J Biol Chem. 2009; 285(6):3625-3632. PMC: 2823503. DOI: 10.1074/jbc.M109.060145. View

Sanchez-Olle G, Duque J, Egido-Gabas M, Casas J, Lluch M, Chabas A . Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Blood Cells Mol Dis. 2009; 42(2):159-66. DOI: 10.1016/j.bcmd.2008.11.002. View

Xu C, Sakai N, Taniike M, Inui K, Ozono K . Six novel mutations detected in the GALC gene in 17 Japanese patients with Krabbe disease, and new genotype-phenotype correlation. J Hum Genet. 2006; 51(6):548-554. DOI: 10.1007/s10038-006-0396-3. View

Sun Y, Liou B, Xu Y, Quinn B, Zhang W, Hamler R . Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem. 2011; 287(6):4275-87. PMC: 3281716. DOI: 10.1074/jbc.M111.280016. View

Vocadlo D, Davies G, Laine R, Withers S . Catalysis by hen egg-white lysozyme proceeds via a covalent intermediate. Nature. 2001; 412(6849):835-8. DOI: 10.1038/35090602. View

Formichi P, Radi E, Battisti C, Pasqui A, Pompella G, Lazzerini P . Psychosine-induced apoptosis and cytokine activation in immune peripheral cells of Krabbe patients. J Cell Physiol. 2007; 212(3):737-43. DOI: 10.1002/jcp.21070. View

Visigalli I, Ungari S, Martino S, Park H, Cesani M, Gentner B . The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche. Blood. 2010; 116(11):1857-66. PMC: 3173985. DOI: 10.1182/blood-2009-12-256461. View

10.

Cohen F, Kelly J . Therapeutic approaches to protein-misfolding diseases. Nature. 2003; 426(6968):905-9. DOI: 10.1038/nature02265. View

11.

Lissens W, Arena A, Seneca S, Rafi M, Sorge G, Liebaers I . A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) region. Hum Mutat. 2007; 28(7):742. DOI: 10.1002/humu.9500. View

12.

Davies G, Henrissat B . Structures and mechanisms of glycosyl hydrolases. Structure. 1995; 3(9):853-9. DOI: 10.1016/S0969-2126(01)00220-9. View

13.

Guce A, Clark N, Rogich J, Garman S . The molecular basis of pharmacological chaperoning in human α-galactosidase. Chem Biol. 2011; 18(12):1521-6. PMC: 3246215. DOI: 10.1016/j.chembiol.2011.10.012. View

14.

Tappino B, Biancheri R, Mort M, Regis S, Corsolini F, Rossi A . Identification and characterization of 15 novel GALC gene mutations causing Krabbe disease. Hum Mutat. 2010; 31(12):E1894-914. PMC: 3052420. DOI: 10.1002/humu.21367. View

15.

Sandhoff K, Kolter T . Topology of glycosphingolipid degradation. Trends Cell Biol. 1996; 6(3):98-103. DOI: 10.1016/0962-8924(96)80999-8. View

16.

Brumshtein B, Greenblatt H, Butters T, Shaaltiel Y, Aviezer D, Silman I . Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem. 2007; 282(39):29052-29058. DOI: 10.1074/jbc.M705005200. View

17.

Nagano S, Yamada T, Shinnoh N, Furuya H, Taniwaki T, Kira J . Expression and processing of recombinant human galactosylceramidase. Clin Chim Acta. 1998; 276(1):53-61. DOI: 10.1016/s0009-8981(98)00095-3. View

18.

Lieberman R, Wustman B, Huertas P, Powe Jr A, Pine C, Khanna R . Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol. 2006; 3(2):101-7. DOI: 10.1038/nchembio850. View

19.

Sulzenbacher G, Driguez H, Henrissat B, Schulein M, Davies G . Structure of the Fusarium oxysporum endoglucanase I with a nonhydrolyzable substrate analogue: substrate distortion gives rise to the preferred axial orientation for the leaving group. Biochemistry. 1996; 35(48):15280-7. DOI: 10.1021/bi961946h. View

20.

Ribbens J, Whiteley G, Furuya H, Southall N, Hu X, Marugan J . A high-throughput screening assay using Krabbe disease patient cells. Anal Biochem. 2012; 434(1):15-25. PMC: 3975245. DOI: 10.1016/j.ab.2012.10.034. View